Degenerative Disease News and Research

RSS

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

Advanced Cell Technology, Inc. announced today that it has completed key animal studies in connection with its Phase I multicenter study using embryonic stem cell derived Retinal Pigment Epithelium (RPE) cells to treat patients with Stargardt's Macular Dystrophy (SMD), for which it filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) in November. The studies demonstrated an excellent safety profile with no safety signals such as tumors or ectopic tissues.

24 Apr 2010

GIS scientists' zebrafish model may aid drug development for PD

Scientists at the Genome Institute of Singapore, a biomedical research institute of the Agency for Science, Technology and Research, have recently developed a zebrafish model for Parkinson's disease that can be used for understanding the mechanism underlying its development. The knowledge gained will be helpful for future screening of new drugs to treat Parkinson's disease.

23 Apr 2010

Alzheimer's Association's hosts conference to educate and support NH people with the disease

Alzheimer's disease can be devastating to families who become caregivers. Anyone seeking more information about Alzheimer's is invited to attend the Alzheimer's Association's "Care to Cure: the latest in research and care giving" conference on Saturday, May 22 in Concord.

23 Apr 2010

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.

20 Apr 2010

70% of COPD patients under-diagnosed due to lack of disease knowledge

"It is high time to demystify COPD in order to better explain the issues and help people who suffer from this disease," says Dr. Jean Bourbeau, Director of the Respiratory, Epidemiology and Clinical Research Unit at the Montreal Chest Institute of the MUHC, and lead investigator of CanCOLD along with Dr. Wan Tan of The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia.

17 Apr 2010

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced that they have received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACU-4429, an investigational oral treatment for dry age-related macular degeneration (dry AMD).

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

Reversal of aging in normal human cells

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced the publication of a scientific paper titled “Spontaneous Reversal of Developmental Aging in Normal Human Cells Following Transcriptional Reprogramming.”

17 Mar 2010

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Electromagnetic pulses significantly decrease pain and inflammation associated with osteoarthritis of the knee, according to Henry Ford Hospital researchers.

7 Mar 2010

Risk of MS increases by many folds following infection with EBV: Study

Researchers from the Harvard School of Public Health, Walter Reed Army Institute of Research, and a team of collaborators have observed for the first time that the risk of multiple sclerosis (MS) increases by many folds following infection with the Epstein-Barr virus (EBV).

5 Mar 2010

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

Advanced Cell Technology, Inc., a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s MA09-hRPE cells for use in the treatment of Stargardt’s Macular Dystrophy (SMD). As a result, the company is eligible to receive a number of benefits, including tax credits, access to grant funding for clinical trials, accelerated FDA approval and allowance for marketing exclusivity after drug approval for a period of as long as seven years.

3 Mar 2010

UCR purchases Nikon BioStation CT technology to assist in stem cell research

Stem cell research at the University of California, Riverside is about to gather speed thanks to the establishment of a new Stem Cell Core Facility (SCCF) - a shared facility providing infrastructure, equipment, and trained personnel for doing stem cell research that ordinarily would not be available in most laboratories.

3 Feb 2010

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

California Stem Cell, Inc. (CSC) and ALS Therapy Development Institute (ALS TDI) are pleased to announce an extension and expansion of their collaboration aimed at advancing a potential stem cell therapy for ALS (amyotrophic lateral sclerosis). This effort will build on work that has already been completed as part of this on-going partnership to understand how stem cells, and their derivatives, may be applied to treatment of this fatal neurodegenerative disease.

3 Feb 2010

QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients

QLT Inc. today announced that it has initiated enrollment in a Phase Ib trial of QLT091001 in pediatric patients with Leber Congenital Amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle.

15 Dec 2009

Mutant ATPase blocks autophagy partway and causes multi-tissue degenerative disease

It's important to finish what you start, say Jeong-Sun Ju and researchers from Washington University School of Medicine, St. Louis. In the December 14, 2009 issue of the Journal of Cell Biology (www.jcb.org), Ju et al. reveal how a mutant ATPase blocks autophagy partway through to cause a multi-tissue degenerative disease.

15 Dec 2009

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

Harvest Technologies Corp. announced today results from the company sponsored 60-patient clinical trial conducted at Sri Ramachandra Medical Center in Chennai, India using the company's BMAC System to treat patients with non-reconstructable Critical Limb Ischemia (CLI). Sri Ramachandra Medical Center is a Harvard Medical international-associated institution based in Chennai, India and one of the largest private healthcare facilities in South Asia.

2 Dec 2009

Advanced Cell Technology files an IND with the FDA for study using embryonic stem cells to treat SMD

Advanced Cell Technology, Inc. announced today that it filed an Investigational New Drug (IND) Application with the US Food and Drug Administration (FDA) to initiate a Phase I/II multicenter study using embryonic stem cell derived retinal cells to treat patients with Stargardt’s Macular Dystrophy (SMD). Among the most common causes of untreatable blindness in the world are degenerative diseases of the retina.

19 Nov 2009

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

$Connection between depression and loss of bone mass leads to osteoporosis and fractures$

Connection between depression and loss of bone mass leads to osteoporosis and fractures

Research carried out among thousands of people has shown a clear connection between depression and a loss of bone mass, leading to osteoporosis and fractures.

9 Nov 2009

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

A team of researchers from Michigan State University and the University of Cincinnati have been awarded a $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant.

15 Oct 2009

Degenerative Disease News and Research

Animal studies demonstrate safety profile of ACT's RPE cell therapy for SMD

GIS scientists' zebrafish model may aid drug development for PD

Alzheimer's Association's hosts conference to educate and support NH people with the disease

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

70% of COPD patients under-diagnosed due to lack of disease knowledge

Acucela, Otsuka Pharmaceutical granted FDA Fast Track designation for ACU-4429 in treatment of dry AMD

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Reversal of aging in normal human cells

Electromagnetic pulses decrease pain and inflammation associated with osteoarthritis of knee

Risk of MS increases by many folds following infection with EBV: Study

Advanced Cell Technology’s MA09-hRPE cells for treatment of SMD: FDA grants orphan drug designation

UCR purchases Nikon BioStation CT technology to assist in stem cell research

CSC, ALS TDI extend collaboration in advancing potential stem cell therapy for ALS

QLT commences enrollment in QLT091001 Phase Ib trial of LCA pediatric patients

Mutant ATPase blocks autophagy partway and causes multi-tissue degenerative disease

Harvest Technologies' BMAC System exhibits potential as an effective treatment for CLI

Advanced Cell Technology files an IND with the FDA for study using embryonic stem cells to treat SMD

SANUWAVE Health reports financial results for the three months ended September 30, 2009

Connection between depression and loss of bone mass leads to osteoporosis and fractures

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News